Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Mar;143(3):923-926.e1.
doi: 10.1016/j.jaci.2019.01.016. Epub 2019 Jan 26.

New insights into the utility of omalizumab

Juan Carlos Cardet  1 , Thomas B Casale  2
Affiliations
Editorial

New insights into the utility of omalizumab

Juan Carlos Cardet et al. J Allergy Clin Immunol. 2019 Mar.

Abstract

Cells that express FcεRIα, including mast cells, basophils, and plasmacytoid dendritic cells (pDCs), are regulated by IgE binding to FcεRIα. Omalizumab binds IgE and prevents its engagement with FcεRIα, thereby downregulating its expression and modulating cell function. Because these cells are implicated in the pathobiology of many allergic and immunologic diseases, as well as host defense mechanisms, it is unsurprising that omalizumab studies continue yielding biologic insights and treatment break-throughs for many diseases. Several recent updates in the biology and use of omalizumab will be presented here, and others will be summarized in Table I, highlighting available biomarker-based personalized approaches.

Keywords: FcεRIα; IgE; allergy; antiviral immunity; asthma; biologic therapy; chronic urticaria; food allergy; immunotherapy; mAb.

PubMed Disclaimer

Conflict of interest statement

Disclosure of potential conflict of interest: J. C. Cardet declares that he has no relevant conflicts of interest.

Figures

FIG 1.
FIG 1.
Omalizumab and the antiviral response in pDCs. Omalizumab blocks IgE and enhances IFN-α responses in pDCs, thereby decreasing susceptibility to viral respiratory tract illness (based on results from the PROSE study).–
See this image and copyright information in PMC

Comment in

  • Reply.
    Cardet JC, Casale TB. Cardet JC, et al. J Allergy Clin Immunol. 2019 Jun;143(6):2336. doi: 10.1016/j.jaci.2019.03.014. Epub 2019 Apr 20. J Allergy Clin Immunol. 2019. PMID: 31014897 No abstract available.
  • The many abilities of omalizumab and the unbeaten path.
    Incorvaia C, Riario-Sforza GG, Ridolo E. Incorvaia C, et al. J Allergy Clin Immunol. 2019 Jun;143(6):2335-2336. doi: 10.1016/j.jaci.2019.02.035. Epub 2019 Apr 20. J Allergy Clin Immunol. 2019. PMID: 31014898 No abstract available.

References

    1. Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol 2015;16: 45–56. - PubMed
    1. Kantor DB, Stenquist N, McDonald MC, Schultz BJ, Hauptman M, Small-wood CD, et al. Rhinovirus and serum IgE are associated with acute asthma exacerbation severity in children. J Allergy Clin Immunol 2016;138: 1467–71.e9. - PMC - PubMed
    1. Gill MA, Bajwa G, George TA, Dong CC, Dougherty II, Jiang N, et al. Counter-regulation between the FcepsilonRI pathway and antiviral responses in human plasmacytoid dendritic cells. J Immunol 2010;184:5999–6006. - PMC - PubMed
    1. Durrani SR, Montville DJ, Pratt AS, Sahu S, DeVries MK, Rajamanickam V, et al. Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children. J Allergy Clin Immunol 2012; 130:489–95. - PMC - PubMed
    1. Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes SJ Jr, Calatroni A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol 2015;136:1476–85. - PMC - PubMed

Publication types

MeSH terms